Catheter Precision, Inc. Price & Performance (VTAK)

A novel AVIM therapy for hypertension has received Breakthrough Device Designation from the FDA, a move expected to accelerate its development and review. This recognition highlights the therapy’s potential to address unmet needs in hypertension treatment, potentially expediting its path to market and benefiting patients sooner.1

Ra Medical Systems has officially rebranded as Catheter Precision, Inc., shifting its strategy entirely to cardiac electrophysiology solutions. The company recently completed 100 ventricular ablation procedures and is seeking CE Mark approval for its LockeT device, aiming to expand its presence in Europe and reinforce its innovation in arrhythmia treatment.23

ARS Pharmaceuticals’ shares declined by nearly 4% today, yet analysts maintain a consensus 'Buy' rating. The company’s intranasal epinephrine product is advancing, and insider trading activity shows more selling than buying. Still, improving short interest trends suggest growing investor confidence in the company’s outlook despite negative earnings.4